⌕
Pediatrix Medical Group · MD · NYSE
Tenet 56 · Mixed
Compare
$31.30−0.32%At closeTenet 56 · Mixed
$31.30−0.10 (−0.32%)
At close: Nov 13, 2026, 4:00 PM ET· NYSE · USD

Pediatrix Medical Group (MD) Stock Checks

How MD measures up against value, income, timing, and long-hold tenets. Every criterion shows the number as of the last close and the pass rule. Always free.

Sources Company filings and computed by Tenet Filings and TenetScreens as of How we compute thisNot investment advice

The tenets below and the 0-100 Tenet Score on this report are two separate computations: each tenet runs its own criteria and its own pass rule, while the score is a percentile composite reported as one of four verdict words (Strong, Solid, Mixed or Weak).

4 / 17 qualify todayas of close, Nov 16, 2026 · computed nightly from our fundamentals DB; point-in-time auditable.
QUALIFIES
4
meet every gate today
BORDERLINE
8
within one input of the gate
FAILS
3
miss at least one gate
UNKNOWN
2
insufficient data to judge
Buffett Qualitydurable moat
~ Borderline
PassesROE ≥ 15%(TTM through Sep 30, 2026)17.2% · ≥ 15.0%
PassesGross margin ≥ 40%(TTM through Sep 30, 2026)100.0% · ≥ 40.0%
FailsNet margin ≥ 15%(TTM through Sep 30, 2026)7.7% · ≥ 15.0%
FailsDebt/equity ≤ 0.5(quarter ending Sep 30, 2026)0.68 · ≤ 0.50
PassesGrowing FCF (multi-yr)(fiscal 2020 to 2025)7.5% per year · > 0
Decided by the pass rule for Buffett Quality.
The pass rule for Buffett Quality is what decides that verdict, and it is not restated here.Buffett Quality under The screens ›Today's Buffett Quality list ›
PassesReturn on assets positive(fiscal 2025)7.4% · > 0
PassesOperating cash flow positive(fiscal 2025)$271.1M · > 0
PassesReturn on assets improving(fiscal 2025)−4.6% → 7.4%
PassesEarnings backed by cash (CFO > net income)(fiscal 2025)$271.1M vs $165.4M
PassesLeverage falling (long-term debt / assets)(fiscal 2025)27.7% → 25.4%
PassesCurrent ratio improving(fiscal 2025)1.47 → 1.66
FailsNo share dilution (≤ +2%)(fiscal 2025)+2.3%
FailsGross margin expanding(fiscal 2025)The reported cost of revenue collapses to a level implying a 100% gross margin, which we treat as a data artefact rather than a real margin, so gross margin could not be measured. It still scores 0 under this module's conservative rule (a point is never awarded without evidence), and it is not counted as one of the signals we were able to measure.no
FailsAsset turnover improving(fiscal 2025)0.94 → 0.85
Decided by the pass rule for Piotroski F-Score.
The pass rule for Piotroski F-Score is what decides that verdict, and it is not restated here. These checks score 6 of 9. 1 of 9 carry no data.Piotroski F-Score under The screens ›Today's Piotroski F-Score list ›
FailsROIC ≥ 15%(TTM through Sep 30, 2026)11.0% · ≥ 15.0%
PassesNet debt/EBITDA ≤ 3×(fiscal 2025: trailing figures for Healthcare are still under review)0.4× · ≤ 3.0×
FailsAltman Z ≥ 3 (safe zone)(TTM through Sep 30, 2026)2.46 · ≥ 3.00
Decided by the pass rule for Munger Compounders.
The pass rule for Munger Compounders is what decides that verdict, and it is not restated here.Munger Compounders under The screens ›Today's Munger Compounders list ›
PassesEBIT > 0(TTM through Sep 30, 2026)$212.6M · > 0
PassesEarnings yield EBIT/EV ≥ 6%(TTM through Sep 30, 2026)8.2% · ≥ 6.0%
PassesReturn on capital ≥ 25%(TTM through Sep 30, 2026)114.5% · ≥ 25.0%
Decided by the pass rule for Magic Formula.
The pass rule for Magic Formula is what decides that verdict, and it is not published separately on the methodology page.About this screen ›Today's Magic Formula® list ›
PassesSize: market cap ≥ $2B$2.4B · ≥ $2.0B
FailsCurrent ratio ≥ 2(quarter ending Sep 30, 2026)1.28 · ≥ 2.00
FailsPositive EPS 10y6y
FailsPays a dividend$0.00 · > 0
PassesEPS growth ≥ 3%/yr(fiscal 2021 to 2025)6.1% per year · ≥ 3.0%
FailsP/E ≤ 15(TTM through Sep 30, 2026)17.16 · ≤ 15.00
FailsP/E × P/B ≤ 22.5(TTM through Sep 30, 2026)49.40 · ≤ 22.50
Decided by the pass rule for Graham Defensive.
The pass rule for Graham Defensive is what decides that verdict, and it is not restated here.Graham Defensive under The screens ›Today's Graham Defensive list ›
FailsPEG < 1 (hist. growth)(P/E TTM through Sep 30, 2026, EPS growth through fiscal 2025)2.81 · < 1.00
FailsEPS growth 10–30%(fiscal 2021 to 2025)6.1% per year · 10.0%–30.0%
Decided by the pass rule for Lynch GARP.
The pass rule for Lynch GARP is what decides that verdict, and it is not restated here.Lynch GARP under The screens ›Today's Lynch GARP list ›
FailsPays a dividend$0.00 · > 0
Unknown — no dataYield in a healthy band (not a yield trap)0.0% · 1.0%–8.0%
Unknown — no dataCovered by free cash flow— · ≥ 1.20
Unknown — no dataEarnings payout not stretched— · ≤ 75.0%
Unknown — no dataBalance sheet can sustain the payout0.4× · ≤ 4.0×
Verdict Unknown for this set.
Verdict Unknown for this set. 1 of 5 checks below carry data. The pass rule for Income & Dividend Safety is not published separately on the methodology page.
FailsPays a dividend$0.00 · > 0
Unknown — no dataAnnual dividend raised 10+ years running (Aristocrat ≥25, King ≥50)— · ≥ 10.00
Unknown — no dataNo dividend cut in the last 5 years—
Unknown — no data5-year dividend growth ≥ 5%/yr— · ≥ 5.0%
Unknown — no dataCovered by free cash flow— · ≥ 1.20
Unknown — no dataPayout not stretched— · ≤ 75.0%
Verdict Unknown for this set.
Verdict Unknown for this set. 1 of 6 checks below carry data.Dividend Growth under The screens ›Today's Dividend Growth list ›
FailsReturn on invested capital ≥ 15% in 4+ of the last 5 years0 of 4 on file
FailsRevenue compounding ≥ 8%/yr over 5 years2.0% per year · ≥ 8.0%
PassesNot diluting: diluted share count flat-to-down (≤ +1%/yr)0.4% · ≤ 1.0%
PassesFree cash flow margin ≥ 12%13.2% · ≥ 12.0%
PassesEarnings backed by cash (operating cash flow ≥ net income)1.51 · ≥ 1.00
Reading: does not hold. Not a gate checkDisciplined buybacks: actively reducing the share count (bonus)reading, not a gate check0.4%
Decided by the pass rule for Quality Compounder.
The pass rule for Quality Compounder is what decides that verdict, and it is not restated here. Lines marked as readings are published beside the checks and are not gate checks.Quality Compounder under The screens ›Today's Quality Compounder list ›
FailsOff its 52-week high by 8–35% (a dip, not a collapse)7.2% · 8.0%–35.0%
FailsDip within its own normal pullback band0.17
PassesNot past where its dips have historically recovered from−0.64
PassesA dip in an uptrend (above a rising 200-day)24.36
PassesHigher-low structure still intactstructure intact · higher low
PassesClear of the earnings blackout (more than 5 days out)96.00 · > 5.00
Decided by the pass rule for Drawdown Context.
The pass rule for Drawdown Context is what decides that verdict, and it is not published separately on the methodology page.
Unknown — no dataA bullish MACD cross within 10 sessions— · ≤ 10.00
PassesReclaimed a rising 50-day EMA28.55
PassesPrinted a higher lowyes
FailsA volume thrust on the turn (≥ 1.2× normal)1.10 · ≥ 1.20
FailsReversal signals fired: 3 of 4 (MACD·MA·HL·Vol)2.00 · ≥ 3.00
Decided by the pass rule for Reversal Evidence.
The pass rule for Reversal Evidence is what decides that verdict, and it is not published separately on the methodology page. 1 of 5 carry no data.
FailsIn the cheap half of its own 5-year valuation range(through fiscal 2025)0.6×
PassesEarnings estimates not being cut0.04
PassesReturns on capital not deteriorating0.11
Decided by the pass rule for Not-a-Value-Trap Gate.
The pass rule for Not-a-Value-Trap Gate is what decides that verdict, and it is not published separately on the methodology page.
PassesOperating profit is positive(TTM through Sep 30, 2026)$212.6M · > 0
PassesReturn on invested capital ≥ 10%(TTM through Sep 30, 2026)11.0% · ≥ 10.0%
PassesA solvent balance sheet (Altman Z ≥ 1.8, net debt/EBITDA ≤ 4)(TTM through Sep 30, 2026)2.5×
PassesQuality score ≥ 5064.90 · ≥ 50.00
PassesRevenue growing over 5 years(fiscal 2020 to 2025)2.0% per year · > 0
Decided by the pass rule for Quality Floor.
The pass rule for Quality Floor is what decides that verdict, and it is not published separately on the methodology page.
A research signal from published criteria, not a recommendation.
FailsDrawdown context7.2% off its 52-week high
FailsReversal evidence2 of 4 signals fired
FailsTrap gate2 of 3 held
PassesQuality floor5 of 5 held
Invalidation level (structure break): below this the dip's structure has broken$21.26
Decided by the pass rule for Qualified Dip.
The pass rule for Qualified Dip is what decides that verdict, and it is not restated here.Qualified Dip under The screens ›Today's Qualified Dip list ›
PassesTrading above its 50-day average27.89
PassesTrading above its 200-day average24.36
Passes50-day average above the 200-day (uptrend stack)27.89
Passes50-day average sloping up0.05 · > 0
Decided by the pass rule for Trend Alignment.
The pass rule for Trend Alignment is what decides that verdict, and it is not published separately on the methodology page.
Passes3-month return in the top half of the universe0.91 · ≥ 0.50
Passes12-minus-1 momentum in the top half of the universe0.68 · ≥ 0.50
PassesRelative strength vs the S&P 500 improving0.00 · > 0
PassesEarnings estimates being revised up0.04
Decided by the pass rule for Relative Strength.
The pass rule for Relative Strength is what decides that verdict, and it is not published separately on the methodology page.
PassesMACD above its signal line1.16
Not scored: see the reason belowBack above the 50-day on a fresh cross (≤10 sessions)This is a two-part reading (price back above the 50-day, and a bullish momentum cross inside 10 sessions) and a dated momentum cross is not on record for this name yet, so it is left unscored rather than counted either way.—
PassesHigher high and higher low (stair-stepping up)higher high · higher low
FailsA volume thrust on the move (≥ 1.2× normal)1.10 · ≥ 1.20
Decided by the pass rule for Momentum Trigger.
The pass rule for Momentum Trigger is what decides that verdict, and it is not published separately on the methodology page. 1 of 4 carry no data.
Average daily swing: elevated0.03
Volatility band width: expanded (wide range)0.89
Distance from its 52-week high: a modest pullback0.07
Every verdict is auditableEach criterion shows the number as of the last close and the pass rule side by side: a receipt, not a rating. Several of these screens publish their rule in full under The screens; each row links to its own section where there is one.
Unknown ≠ failAn “— Unknown” verdict means the inputs were insufficient: context, not a signal, and never counted as a fail.

How many investing rule sets does Pediatrix Medical Group pass?

Pediatrix Medical Group qualifies on 4 of 17 rule sets as of 2026-11-16, with 8 borderline and 3 failing.

Does Pediatrix Medical Group meet the Graham Defensive criteria?

Pediatrix Medical Group fails the Graham Defensive rule set as of 2026-11-16.

Does Pediatrix Medical Group meet the Buffett Quality criteria?

Pediatrix Medical Group is borderline on the Buffett Quality rule set as of 2026-11-16.

Computed from our fundamentals DB; historical-CAGR PEG basis for Lynch. Research, not investment advice. Tenet's rulesets are independently developed from publicly available sources, and Tenet is not affiliated with, sponsored by, endorsed by or otherwise associated with any referenced investor or trademark owner. Full notice. MAGIC FORMULA is a trademark of MagicFormulaInvesting.com LLC.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.